GlassScriptPhysician profile
Jill E Hemmelgarn
NPI 1700221132
$4,413.87
in general payments reported to CMS, 2019-2025
33 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $342 · 2021: $55.04 · 2022: $1,108 · 2023: $761 · 2024: $281 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.44 |
| Education | $239.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.90 | 2019-2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $429.96 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $344.42 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $304.26 | 2022-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $244.51 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.86 | 2022-2025 | |
| Amgen INC. | $241.79 | 2019-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $237.35 | 2020-2023 | Acthar |
| Novo Nordisk INC | $220.96 | 2023-2025 | Ozempic, Wegovy |
| Akebia Therapeutics INC | $208.41 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $164.36 | 2022-2024 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $159.57 | 2019 | |
| Opko Pharmaceuticals, LLC | $115.42 | 2019-2025 | Rayaldee |
| Lundbeck LLC | $104.52 | 2019-2020 | |
| Ardelyx, INC. | $102.47 | 2024 | Xphozah 30 Mg |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $101.85 | 2022-2025 | Velphoro |
| Takeda Pharmaceuticals U.S.A., INC. | $99.78 | 2022-2023 | Gattex |
| Travere Therapeutics, INC. | $91.95 | 2022-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $82.83 | 2019 | |
| Medtronic, INC. | $50.39 | 2024 | Symplicity G3 |
| Daiichi Sankyo INC. | $49.41 | 2019-2022 | |
| Shire North American Group INC | $48.62 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.63 | 2022-2023 | Purified Cortrophin Gel |
| Amag Pharmaceuticals, INC. | $35.97 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.93 | 2019 | |
| Genentech USA, INC. | $24.22 | 2019 | |
| Genzyme Corporation | $23.64 | 2023 | |
| Glaxosmithkline, LLC. | $20.62 | 2022 | |
| Horizon Therapeutics Plc | $19.03 | 2020 | |
| Philips North America LLC | $17.38 | 2025 | Vest Therapy Und |
| Renalytix Ai, INC. | $13.36 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hemmelgarn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.